Experimental weight-loss combo EloraTZP shows 23.3% average weight loss in Phase 2b trial

In a Phase 2b study of people with Type 2 diabetes, experimental eloralintide plus Zepbound (EloraTZP) was linked to 23.3% average weight loss at the highest dose, versus 14.8% with Zepbound alone; figures include projected results for dropouts.

Detected & updated continuously · Source: Nebula